Alkermes Plc Stock Price, News & Analysis

Alkermes hosted an enlightening discussion featuring Dr. Kevin M. Simon, Boston's Chief Behavioral Health Officer, addressing implicit bias and mental health stigma in minority communities. Dr. Simon highlighted the mental health challenges faced by Dr. Martin Luther King Jr. and emphasized the importance of allyship in promoting diversity and inclusion. Alkermes continues to focus on ending the stigma surrounding mental health issues, aligning with its commitment to innovation in neuroscience and oncology.

With a global presence, Alkermes develops medicines for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, alongside an evolving pipeline for neurodegenerative disorders and cancer.

On March 15, 2023, Alkermes plc (NASDAQ: ALKS) announced its participation in a fireside chat at the Stifel 2023 CNS Days. The event will take place on March 29, 2023, at 9:00 a.m. ET (2:00 p.m. BST). The live webcast can be accessed on the Investors tab of Alkermes' website and will be available for 14 days post-event. Alkermes is a global biopharmaceutical company focused on neuroscience and oncology, offering products for alcohol and opioid dependence, schizophrenia, and bipolar I disorder. For more details, visit www.alkermes.com.

Alkermes reported a revenue of $1.11 billion for 2022, down from $1.17 billion in 2021, with a GAAP loss per share of $0.97. Non-GAAP earnings per share stood at $0.34. The company generated $96 million in net sales from LYBALVI® in its first full year of launch and experienced double-digit growth in sales of VIVITROL® and ARISTADA®. For 2023, Alkermes projects total revenue between $1.13 billion and $1.25 billion and a GAAP net loss between $160 million and $200 million, anticipating continued growth in proprietary products and a planned separation of its oncology business.

Alkermes highlights its organizational culture founded on compassion, scientific integrity, and impactful contributions to society. This commitment is evident in their team dynamics and innovative approaches to healthcare challenges. The company aims to engage stakeholders through various channels, promoting their values and efforts in enhancing public health. The press release encourages viewers to learn more about the company culture via a dedicated video, emphasizing the importance of the human element in their operations.

Alkermes plc (Nasdaq: ALKS) will conduct a conference call and webcast on February 16, 2023, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2022 financial results. The management will also outline financial expectations for 2023 and provide company updates. Interested parties can access the webcast through Alkermes' website. U.S. callers can join by dialing +1 877 407 2988, while international callers can reach +1 201 389 0923. A replay will be available two hours post-event.

Alkermes has released an animation that explores how alcohol dependence impacts the brain, aligning with the conclusion of Dry January. The initiative aims to raise awareness about alcohol-related issues and includes a questionnaire designed to help individuals assess their drinking habits. For those interested, additional multimedia content and ESG storytelling are available through Alkermes' profile on 3blmedia.com. This educational effort reflects Alkermes' commitment to addressing alcohol dependence and supporting individuals seeking help.

Alkermes plc (NASDAQ: ALKS) announced that its investigational immunotherapy, nemvaleukin alfa, has received an Innovation Passport from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for treating mucosal melanoma. This designation facilitates accelerated market access and provides benefits such as a 150-day assessment for Marketing Authorization Applications (MAA). Previously, nemvaleukin received Orphan Drug and Fast Track designations from the U.S. FDA. The ILAP program, launched in January 2021, aims to speed up access to essential medicines for serious health conditions.